ReviewJournal of the Egyptian National Cancer Institute2026
Immune organoids for Africa: a roadmap for bridging the innovation gap in infectious diseases and cancer research.
Review in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSub-Saharan Africa bears approximately 25% of the global disability-adjusted life-year (DALY) burden yet contributes fewer than 3% of global health research outputs. HIV/AIDS, tuberculosis (TB), and malaria coexist with a rising cancer burden, with attributable mortality projected to increase 75% by 2050. Fewer than 0.2% of genome-wide association study (GWAS) participants are of African ancestry, constraining precision medicine relevance. Conventional two-dimensional cultures and murine models inadequately replicate immune dynamics, tissue-level pathogenesis, and African pharmacogenomics. Immune organoids (three-dimensional microphysiological constructs) offer human-relevant platforms for mechanistic immunology, drug screening, vaccine evaluation, and precision oncology.
methodA narrative review was conducted across PubMed, Scopus, Web of Science, and Google Scholar (January 2019-June 2025), integrating technical descriptors (lymph node-on-a-chip, patient-derived organoids, microphysiological systems) with regional keywords (sub-Saharan Africa, genomic sovereignty, STISA-2034, frugal bioengineering). Gray literature from WHO, World Bank, and Africa CDC was incorporated. Thematic synthesis identified technological advances, infrastructural barriers, regulatory gaps, and sociopolitical determinants of adoption.
resultLymph node-on-a-chip, tonsil-derived, and tumor-immune co-culture organoids enable high-fidelity interrogation of host-pathogen and tumor-immune interactions. Adoption is constrained by infrastructure deficits, reagent costs, energy instability, bioinformatics gaps, and nascent regulatory frameworks. Scalable solutions include a three-tier hub framework (Coordinator-Generator-Collaborator), ABCOMICS for continental genomic data governance, frugal LCD-based bioprinting, and passive microfluidic perfusion. Harmonized ethical guidelines and community-engaged consent are essential for genomic sovereignty.
conclusionA phased, STISA-2034-aligned roadmap integrating frugal bioengineering, ethical governance, and targeted capacity-building can position Africa as a global leader in human-centric biomedical research, accelerating precision medicine, pandemic preparedness, and health equity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.